ADOM - We Believe Genprex Is A Disaster In The Making
Overview
Genprex (GNPX) is a newly-listed company with only 4 full-time employees that describes itself as “a clinical stage gene therapy company developing a new approach to treating cancer.”
Despite the supposed “new approach” to cancer treatment, we learned that the foundation of Genprex’s key product candidate largely consists of intellectual property that was legally abandoned during the 2009 bankruptcy of Introgen, the founder’s previous failed public company. Introgen in turn had access to the intellectual property since as early as 2001 and was unable to commercialize or even meaningfully advance its development